SCHEDULE: TD Bank Group Discloses 5.4% Stake in Stoke Therapeutics

The Toronto-Dominion Bank and its subsidiary TD Securities Inc. have reported beneficial ownership of 5.4% of Stoke Therapeutics, Inc. common stock as of March 31, 2026.

Summary

• The Toronto-Dominion Bank (TD Bank) and its subsidiary, TD Securities Inc. (TDSI), have jointly filed a Schedule 13G, indicating their beneficial ownership of Stoke Therapeutics, Inc. common stock.
• As of March 31, 2026, TD Bank beneficially owns 3,173,258 shares, holding sole voting and dispositive power.
• TDSI beneficially owns 2,300 shares, also holding sole voting and dispositive power.
• The aggregate beneficial ownership reported is 3,175,558 shares, representing 5.4% of the class of securities.
• TD Bank is the sole owner of TDSI and may be deemed to hold an indirect interest in the shares reported by TDSI, though it disclaims ownership beyond its pecuniary interest.
• Both entities certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports ownership and does not contain operational or financial performance updates for Stoke Therapeutics itself.

Positives

• The filing indicates a significant institutional investor, TD Bank Group, holds a notable stake (5.4%) in Stoke Therapeutics.
• The reporting entities are established financial institutions, suggesting a potentially stable and informed investment.

Negatives

• The filing does not provide details on the acquisition cost or the investment strategy behind this stake.
• TD Bank's disclaimer of ownership beyond its pecuniary interest in TDSI's holdings could imply a nuanced or limited direct control.

Risks

• The filing does not explicitly mention any risks associated with the investment.
• Potential future changes in TD Bank Group's investment strategy could lead to divestment, impacting Stoke Therapeutics' stock.

Future Outlook

The filing does not contain forward-looking statements or guidance from Stoke Therapeutics. The information pertains to the ownership stake of TD Bank Group.

Management Comments

• TD Bank may be deemed to hold an indirect interest in the shares reported herein by TDSI by virtue of its ownership of TDSI.
• TD Bank disclaims ownership of the shares reported herein by TDSI except to the extent of its pecuniary interest therein.
• Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) of the US Securities Exchange Act of 1934 or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate or other group for the purpose of acquiring, holding or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.

Industry Context

StockSavvy.ai notes that the disclosure of a significant stake by a major financial institution like TD Bank Group in a biotechnology company like Stoke Therapeutics often signals confidence in the company's technology or market potential, especially in the competitive biotech landscape where institutional backing is crucial for development and growth.

Stakeholder Impact

• Shareholders may view the increased institutional ownership positively, potentially indicating confidence in the company's future prospects.
• The investment by TD Bank Group could enhance Stoke Therapeutics' credibility within the financial community.

Next Steps

• Monitor future filings from TD Bank Group for any changes in their stake in Stoke Therapeutics.
• Observe Stoke Therapeutics' operational and financial performance for insights into the value of TD Bank Group's investment.

Key Dates

Keywords

Stoke Therapeutics, Schedule 13G, The Toronto-Dominion Bank, TD Securities Inc., beneficial ownership, common stock, institutional investor, 5.4%, SEC filing